Andelyn, Ohio State Partner on GMP Mfg. of Novel Gene Therapies

Andelyn Biosciences, Inc., a cell and gene therapy CDMO, has partnered with The Ohio State University Gene Therapy Institute for the development and clinical manufacturing of novel gene therapies.

The collaboration was established to facilitate the pathway to bring Ohio State’s investigational gene therapies for a multitude of neurological disorders, such as Parkinson’s, amyotrophic lateral sclerosis (ALS), and Huntington’s, from concept through to manufacturing for clinical trials.

Principal investigators at Ohio State will be able to leverage Andelyn’s adherent and suspension platforms and extensive viral vector development and process optimization experience, along with its full manufacturing capabilities. Ohio State and Andelyn aim to maximize program efficiencies and accelerate timelines to the clinic.

In a statement, Andelyn said that developing novel gene therapies together further strengthens the existing working relationship between Ohio State and Andelyn and offers great hope for patients afflicted with genetically based neurological diseases. The collaboration aims to ensure Ohio State’s gene therapies advance as fast as possible and with the highest quality.

Matt Niloff, chief commercial officer of Andelyn, said, “We are privileged to serve as a critical resource for Ohio State’s premier Gene Therapy Institute, supporting life-changing gene therapy programs with our pre-clinical and GMP manufacturing capabilities.” 

Russell Lonser, Director of Ohio State’s Gene Therapy Institute, said, “There’s such a critical need to develop effective therapies for ALS, Huntington’s disease, and Parkinson’s disease. We believe that gene therapy offers new hope to those suffering from these devastating neurological disorders and look forward to accelerating the development of new transformative therapies.”